SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has ...

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing ...

Moleculin Biotech (MBRX) announced the completion of its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of subjects with acute myeloid leukemia.

SK10, the first Bacteroides fragilis-based live biotherapeutic product (LBP) obtained FDA IND approval, is also the first LBP of Next-generation probiotics developed by Chinese biotech company that ...

HOUSTON, March 23, 2026 (GLOBE NEWSWIRE)-- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AURN001 is an allogeneic cell therapy being evaluated ...

NKGen Biotech (NKGN) announced the presentation of two posters, on its first-in-kind, autologous, non-genetically modified NK cell product, troculeucel, in Alzheimer’s Disease, AD. The posters ...

Gilead to Buy Biotech for $5 Billion. How the Deal Strengthens Its Ovarian Cancer Fight. Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in ...

Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...

First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company History Early Blinded Results Show 40% Remission Rate Across Difficult-to-Treat ...